Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01506908 · ClinicalTrials.gov registry record · Phase 2
Provoked Craving Assessment
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
NCT01506908: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT01506908 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 323 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (143% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01506908, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
Study Summary
Evaluation of the ability of a nicotine mini lozenge to provide early relief of craving for a cigarette in smokers
Primary Outcome
Participants completed a nicotine craving assessment consisting of following five items: I have a desire for a cigarette right now, if it were possible I would smoke right now, All I want right now is a cigarette, I have an urge for a cigarette, I crave a cigarette right now. All participants indicated their craving intensity on a pre-drawn 100 mm scale ranging from 0 (disagree) to 100 (agree). At the end of the craving assessment period, mean VAS score was measured.
Interventions
- DRUG Placebo
- DRUG oral nicotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT01506908 record still lists
NCT01506908 is an interventional study that assigns participants to a tested intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (143% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01506908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01506908 about?
NCT01506908 is a clinical study titled "Provoked Craving Assessment". Evaluation of the ability of a nicotine mini lozenge to provide early relief of craving for a cigarette in smokers
What is the current status of trial NCT01506908?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2011-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01506908?
The interventions under investigation include: Placebo (DRUG), oral nicotine (DRUG).
Who is sponsoring clinical trial NCT01506908?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01506908's enrollment target sits among peer trials
323 150th of 2000 higher than 1,851 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia